People: Forest Laboratories Inc (FRX)

Summary

Name	Age	Since	Current Position
Howard Solomon	82	2010	Chairman of the Board, President, Chief Executive Officer
Francis Perier	49	2010	Chief Financial Officer, Executive Vice President - Finance and Administration
Elaine Hochberg	53	2010	Executive Vice President and Chief Commercial Officer
Jerome Lynch		2010	Senior Vice President - Sales
David Solomon		2010	Senior Vice President - Corporate Development and Strategic Planning
Marco Taglietti	50	2010	Senior Vice President - Research and Development, President - Forest Research Institute
Kevin Walsh		2010	Senior Vice President and Director - Operations
Kenneth Goodman	62	2011	Presiding Independent Director
Nesli Basgoz		2006	Director
Christopher Coughlin	60	2011	Director
Gerald Lieberman		2011	Director
Lawrence Olanoff	58	2010	Director
Lester Salans	74	1998	Director
Brenton Saunders		2011	Director
Peter Zimetbaum	46	2009	Director
Pierre Legault	49	2012	Independent Director

» Insider Trading

Biographies

Name	Description
Howard Solomon	Mr. Howard Solomon has been the Chairman of the Board, President, Chief Executive Officer of Forest Laboratories, Inc. Mr. Solomon is the Chairman of the Board and has served as Chief Executive Officer since 1977. The Company believe that Mr. Solomon’s experience as a senior executive in industry, knowledge of the Company and its day-to-day operations, and his strategic vision for the Company qualify him to serve on the Board.
Francis Perier	Mr. Francis I. Perier, Jr., is Chief Financial Officer, Executive Vice President - Finance and Administration of Forest Laboratories, Inc. effective December 31, 2010. From March 2004 until joining in September 2004, Mr. Perier was Vice President – Finance – Operations Planning – Americas Medicines at Bristol-Myers Squibb. For eight years prior to March 2004, Mr. Perier served in senior financial positions at Bristol-Myers Squibb including four years as Vice President – Finance, Planning, Business Development and Information Technology at its ConvaTec Division. Prior to that, Mr. Perier had been a partner at Deloitte & Touche, LLP.
Elaine Hochberg	Ms. Elaine Hochberg is the Executive Vice President and Chief Commercial Officer of Forest Laboratories, Inc effective December 31, 2010. She served as the Senior Vice President – Marketing and Chief Commercial Officer of the company. She was the Senior Vice President – Marketing since December 1999 and Chief Commercial Officer since December 2007. Ms. Hochberg joined in June 1997 as Vice President – Marketing of wholly-owned subsidiary Forest Pharmaceuticals, Inc. In February 1998, she was promoted to Vice President – Marketing of the Company. Prior to joining in 1997, Ms. Hochberg was Assistant Vice President – Marketing at Wyeth-Lederle Laboratories.
Jerome Lynch	Mr. Jerome Lynch is the Senior Vice President - Sales of Forest Laboratories, Inc. effective December 31, 2010. He was the Senior Vice President Sales of Forest Pharmaceuticals. He presently is responsible for all Territory and Specialty Sales, and Sales Analytics and will, in addition, become responsible for Sales Training. He joined Forest in 1992, and has served in various sales management roles while at Forest.
David Solomon	Mr. David Solomon is the Senior Vice President - Corporate Development and Strategic Planning of Forest Laboratories, Inc. effective December 31, 2010. He is presently responsible for the Business Development and Alliance Management groups, including the expanding North American and European operations. He joined Forest in 2001.
Marco Taglietti	Dr. Marco Taglietti, M.D., is the Senior Vice President - Research and Development, President - Forest Research Institute of Forest Laboratories, Inc effective December 31, 2010. Dr. Taglietti joined Forest in August 2007 as Executive Vice President – Research and Development and Chief Medical Officer of wholly-owned subsidiary Forest Research Institute, Inc. Prior to joining , Dr. Taglietti was Senior Vice President and Head of Global Research and Development at Stiefel Laboratories for three years. Prior to that, Dr. Taglietti was at Schering-Plough for twelve years in positions of increasing responsibilities including Vice President – Worldwide Clinical Research for Anti-Infectives, Oncology, CNS, Endocrinology and Dermatology.
Kevin Walsh	Mr. Kevin Walsh is the Senior Vice President and Director - Operations of Forest Laboratories, Inc effective December 31, 2010. He is presently responsible for Information Systems and Manufacturing Operations, including all Supply Chain, Technology Transfer and Facilities Engineering functions and will, in addition, become responsible for Corporate Compliance. He joined Forest as Vice President, Information Systems, in 2003 having prior served as Vice President of Information Technology at Roche Pharmaceuticals.
Kenneth Goodman	Mr. Kenneth E. Goodman has been appointed as Presiding Independent Director of Forest Laboratories, Inc. He is the former President and Chief Operating Officer of Forest (December 1998 to September 2006). For eighteen years prior thereto, Mr. Goodman served as Forest’s Vice President – Finance and Chief Financial Officer and in addition served as Executive Vice President – Operations since February 1998, during which time he helped to oversee a expansion of the scope of the operations of the Company. From 1975 to 1980, he served as a senior financial officer at Wyeth (now part of Pfizer Incorporated). Mr. Goodman’s knowledge of Forest’s operations and his in financial matters make him a member of the Board and provide an important interface between management and the Board.
Nesli Basgoz	Dr. Nesli Basgoz, M.D., is Director of Forest Laboratories, Inc. Dr. Basgoz is the Associate Chief for Clinical Affairs, Division of Infectious Diseases, Massachusetts General Hospital (MGH) and serves as Associate Professor of Medicine at Harvard Medical School. Dr. Basgoz previously served as Clinical Director, Infectious Diseases Division of MGH. Dr. Basgoz’s experience with clinical trials provides her with the skills and experience necessary to effectively advise the Board and management with respect to the clinical trial process. Moreover, in infectious diseases allows Dr. Basgoz to advise the Board and management with respect to the Company’s current and potential portfolio drugs within the relevant indications.
Christopher Coughlin
Gerald Lieberman
Lawrence Olanoff	Dr. Lawrence S. Olanoff, M.D., Ph.D. is the Director of Forest Laboratories, Inc. He was the President and Chief Operating Officerof the company until December 31, 2010. From July 2005 to October 2006, Dr. Olanoff served as President and Chief Executive Officer at Celsion Corporation where he was also a director from July 2005 to July 2006. For the ten years prior to July 2005, Dr. Olanoff served as Executive Vice President – Chief Science Officer at Forest. Dr. Olanoff’s knowledge of the pharmaceutical industry, his service as a senior executive and his experience with and participation in research and development combine to qualify him to serve as a director of Forest.
Lester Salans	Dr. Lester B. Salans, M.D., is Director of Forest Laboratories, Inc. He is a Clinical Professor and member of the Clinical Attending Staff – Internal Medicine at the Mount Sinai Medical School. Prior thereto, Dr. Salans served as the Vice President of Academic and Scientific Affairs and Vice President of Preclinical Research at Sandoz Pharmaceutical Corporation. Dr. Salans is a former Director of the National Institutes of Health and the National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases and is a frequent lecturer on diabetes. Dr. Salans’ medical expertise in the fields of diabetes mellitus, obesity and endocrinology allows him to advise the Board and management generally on matters relating to research and development and more specifically with respect to the Company’s current and potential portfolio drugs within such indications.
Brenton Saunders
Peter Zimetbaum	Dr. Peter J. Zimetbaum M.D., serves as Director of Forest Laboratories Inc. Dr. Zimetbaum served as Director of Clinical Electrophysiology at Beth Israel Deaconess Medical Center in Boston (BIDMC) from 2001 to 2005. Since 2005, he has served as Director of Clinical Cardiology at BIDMC. Additionally, since 2006, Dr. Zimetbaum has been an Associate Professor of Medicine at the Harvard Medical School. Dr. Zimetbaum received his M.D. degree from Albert Einstein College of Medicine in 1990 and is board certified in both Cardiovascular Medicine and Cardiovascular Electrophysiology. Dr. Zimetbaum’s experience in the practice of medicine and clinical trials allows him to advise the Board and management with respect to the perspectives of physicians and other healthcare providers who use the Company’s products as well as the clinical trial process. Moreover, Dr. Zimetbaum’s expertise in cardiology is a resource to the Board and management in analyzing current and potential portfolio drugs within the relevant indications.
Pierre Legault	Mr. Pierre Legault has been appointed as Independent Director of Forest Laboratories Inc., effective August 15, 2012. Mr. Legault had previously served as chief financial officer at OSI Pharmaceuticals, and also held executive positions as several drug maker and drug retail firms.

Basic Compensation

Name	Fiscal Year Total
Howard Solomon	8,267,240
Francis Perier	3,011,380
Elaine Hochberg	3,599,290
Jerome Lynch	--
David Solomon	--
Marco Taglietti	2,532,540
Kevin Walsh	--
Kenneth Goodman	1,932,710
Nesli Basgoz	--
Christopher Coughlin	--
Gerald Lieberman	--
Lawrence Olanoff	5,388,180
Lester Salans	--
Brenton Saunders	--
Peter Zimetbaum	--
Pierre Legault	--

As Of 30 Mar 2010

Options Compensation

Name	Options	Value
Howard Solomon	7,400,000	137,746,800
Francis Perier	150,000	215,500
Elaine Hochberg	857,780	14,215,373
Jerome Lynch	0	0
David Solomon	0	0
Marco Taglietti	0	0
Kevin Walsh	0	0
Kenneth Goodman	6,700,000	142,130,000
Nesli Basgoz	0	0
Christopher Coughlin	0	0
Gerald Lieberman	0	0
Lawrence Olanoff	1,338,000	28,007,674
Lester Salans	0	0
Brenton Saunders	0	0
Peter Zimetbaum	0	0
Pierre Legault	0	0

Insider Trading

Name	Shares Traded	Price
BASGOZ NESLI	6,321	$37.44
BASGOZ NESLI	1,663	$37.45
BASGOZ NESLI	212	$37.44
BASGOZ NESLI	1,979	$37.49
BASGOZ NESLI	1,425	$37.46
BASGOZ NESLI	403	$37.50
BASGOZ NESLI	4,000	$26.25
BASGOZ NESLI	197	$37.49
BASGOZ NESLI	5,621	$28.23
OLANOFF LAWRENCE S	543	$36.77
WEINSTEIN HERSCHEL S	800	$0.00
MEURY WILLIAM	3,445	$35.81
MEURY WILLIAM	600	$35.83
MEURY WILLIAM	1,300	$35.82
MEURY WILLIAM	11,350	$30.00
MEURY WILLIAM	200	$35.86
MEURY WILLIAM	100	$35.78
MEURY WILLIAM	200	$35.88
MEURY WILLIAM	600	$35.79
MEURY WILLIAM	9,048	$35.65
MEURY WILLIAM	400	$35.85
MEURY WILLIAM	15,000	$24.12
MEURY WILLIAM	400	$35.84
MEURY WILLIAM	2,400	$35.80
MEURY WILLIAM	5,419	$35.75

» Full list on Insider Trading

People: Forest Laboratories Inc (FRX)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: